Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Anis Askarizadeh"'
Autor:
Amin Mehrabian, Saba Dadpour, Mohammad Mashreghi, Javad Zarqi, Anis Askarizadeh, Ali Badiee, Leila Arabi, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari
Publikováno v:
IET Nanobiotechnology, Vol 17, Iss 2, Pp 112-124 (2023)
Abstract Several obstacles limit the efficacy of brain tumour treatment, most notably the blood‐brain barrier (BBB), which prevents the brain uptake of the majority of accessible medicines due to tight junctions. The presence of glutathione (GSH) r
Externí odkaz:
https://doaj.org/article/daff2480ef8942baacd8e408881c310b
Autor:
Anis Askarizadeh, Mohammad Mashreghi, Elaheh Mirhadi, Farshad Mirzavi, Vahid Heravi Shargh, Ali Badiee, Seyedeh Hoda Alavizadeh, Leila Arabi, Mahmoud Reza Jaafari
Publikováno v:
Cancer Nanotechnology, Vol 14, Iss 1, Pp 1-26 (2023)
Abstract Background Colorectal cancer is one of the prominent leading causes of fatality worldwide. Despite recent advancements within the field of cancer therapy, the cure rates and long-term survivals of patients suffering from colorectal cancer ha
Externí odkaz:
https://doaj.org/article/53af15c3c2984d28b0b3b7b4cd9f010c
Autor:
Saba Dadpour, Amin Mehrabian, Mahdieh Arabsalmani, Elaheh Mirhadi, Anis Askarizadeh, Mohammad Mashreghi, Mahmoud Reza Jaafari
Publikováno v:
IET Nanobiotechnology, Vol 16, Iss 7-8, Pp 259-272 (2022)
Abstract The size of nanoliposome‐encapsulated drugs significantly affects their therapeutic efficacy, biodistribution, targeting ability, and toxicity profile for the cancer treatment. In the present study, the biodistribution and anti‐tumoral a
Externí odkaz:
https://doaj.org/article/976762e36fb642269d4acca83f69b3d4
Autor:
Elaheh Mirhadi, Mohammad Mashreghi, Anis Askarizadeh, Amin Mehrabian, Seyedeh Hoda Alavizadeh, Leila Arabi, Ali Badiee, Mahmoud Reza Jaafari
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-17 (2022)
Abstract In this study redox-sensitive (RS) liposomes manufactured using 10,10′-diselanediylbis decanoic acid (DDA), an organoselenium RS compound, to enhance the therapeutic performance of doxorubicin (Dox). The DDA structure was confirmed by 1H N
Externí odkaz:
https://doaj.org/article/b438caecdf5b4163bc3ac3550eb58143
Autor:
Amin Mehrabian, Saba Dadpour, Mohammad Mashreghi, Javad Zarqi, Anis Askarizadeh, Ali Badiee, Leila Arabi, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari
Publikováno v:
IET nanobiotechnologyREFERENCES.
Several obstacles limit the efficacy of brain tumour treatment, most notably the blood-brain barrier (BBB), which prevents the brain uptake of the majority of accessible medicines due to tight junctions. The presence of glutathione (GSH) receptors on
Autor:
Mohammad Mashreghi, Mahdi Faal Maleki, Anis Askarizadeh, Helaleh Farshchi, Leila Farhoudi, Mahda Sadat Nasrollahzadeh, Mahere Rezazade Bazaz, Farzin Hadizadeh, Mahmoud Reza Jaafari
Publikováno v:
Chemistry and physics of lipids. 247
This study designed and synthesized a cost-effective azo-based hypoxia-sensitive linker (AHSL) using commercially accessible, inexpensive raw materials and simple methods to apply in cationic nanoliposomes. Then, AHSL was post-inserted into the catio
Publikováno v:
Expert Opinion on Drug Delivery. 17:167-187
Introduction: Leishmaniasis is a neglected tropical infection caused by several species of intracellular protozoan parasites of the genus Leishmania. It is strongly believed that the development of vaccines is the most appropriate approach to control
Autor:
Farzin Hadizadeh, Mahda Sadat Nasrollahzadeh, Mohammad Mashreghi, Helaleh Farshchi, Mahdi Faal Maleki, Anis Askarizadeh, Leila Farhoudi, Mahmoud Reza Jaafari
The goal of this study was to prepare cationic nanoliposomal doxorubicin in which PEG molecule attached to the liposome via a hypoxia-sensitive azo linker. The cost-effective hypoxia-sensitive molecule (HSM) was synthesized composing of C18H37 lipoph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e77b24715bbd7bd0d5b4d65aac7eb39
https://doi.org/10.21203/rs.3.rs-832393/v1
https://doi.org/10.21203/rs.3.rs-832393/v1
Autor:
Elaheh, Mirhadi, Fatemeh, Gheybi, Nadya, Mahmoudi, Maliheh, Hemmati, Fatemeh, Soleymanian, Atefeh, Ghasemi, Anis, Askarizadeh, Mehrdad, Iranshahi, Mahmoud Reza, Jaafari, Seyedeh Hoda, Alavizadeh
Publikováno v:
International Journal of Pharmaceutics. 623:121946
Cis-Diaminedichloroplatinum (cisplatin, CDDP) remained among the most widely used anti-cancer agents; however, management of the dose-limiting side effects is still a great hurdle to its therapeutic potential. In the framework of this investigation,
Publikováno v:
Expert opinion on drug delivery. 17(2)